Assessment of 186Re chelate-conjugated bisphosphonate for the development of new radiopharmaceuticals for bones

Nuclear Medicine and Biology

Volumn 34, Issue 1, 2007, Pages 79-87

  Uehara, Tomoya ^a   Jin, Zhe Long ^a   Ogawa, Kazuma ^b   Akizawa, Hiromichi ^a   Hashimoto, Kazuyuki ^c   Nakayama, Morio ^d   Arano, Yasushi ^a  

^a CHIBA UNIVERSITY   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

^c JAPAN ATOMIC ENERGY AGENCY   (Japan)

^d NAGASAKI UNIVERSITY   (Japan)

Author keywords

Bisphosphonate; Bone pain; Bone scintigraphy; Palliative treatment; Rhenium

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; RHENIUM 186; CHELATING AGENT; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; RHENIUM;

ANIMAL EXPERIMENT; ARTICLE; BONE; CHELATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PLASMA CLEARANCE; RADIOACTIVITY; ANIMAL; ANTIBODY SPECIFICITY; CHEMISTRY; DRUG SCREENING; EVALUATION; METABOLIC CLEARANCE RATE; SYNTHESIS; TISSUE DISTRIBUTION;

ANIMALS; CHELATING AGENTS; DIPHOSPHONATES; DRUG EVALUATION, PRECLINICAL; METABOLIC CLEARANCE RATE; MICE; ORGAN SPECIFICITY; RADIOISOTOPES; RADIOPHARMACEUTICALS; RHENIUM; TISSUE DISTRIBUTION;

EID: 33845949319     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2006.10.001     Document Type: Article

References (35)

1. Coleman R.E., Woll P.J., Miles M., Scrivener W., and Rubens R.D. Treatment of bone metastases from breast cancer with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD). Br J Cancer 58 (1988) 621-625
2. Morris M.J., and Scher H.I. Clinical approaches to osseous metastases in prostate cancer. Oncologist 8 (2003) 161-173
3. Rustoen T., Moum T., Padilla G., Paul S., and Miaskowski C. Predictors of quality of life in oncology outpatients with pain from bone metastasis. J Pain Symptom Manage 30 (2005) 234-242
4. Di Lorenzo G., Autorino R., Ciardiello F., Raben D., Bianco C., Troiani T., et al. External beam radiotherapy in bone metastatic prostate cancer: impact on patients' pain relief and quality of life. Oncol Rep 10 (2003) 399-404
5. 186ReHEDP. Inorg Chem 36 (1997) 3055-3063
6. 186Re-HEDP for metastatic bone pain in breast cancer patients. Eur J Nucl Med Mol Imaging 31 Suppl 1 (2004) S162-S170
7. Maxon III H.R., Schroder L.E., Thomas S.R., Hertzberg V.S., Deutsch E.A., Scher H.I., et al. Re-186(Sn) HEDP for treatment of painful osseous metastases: initial clinical experience in 20 patients with hormone-resistant prostate cancer. Radiology 176 (1990) 155-159
8. Englaro E.E., Schroder L.E., Thomas S.R., Williams C.C., and Maxon III H.R. Safety and efficacy of repeated sequential administrations of Re-186(Sn)HEDP as palliative therapy for painful skeletal metastases. Initial case reports of two patients. Clin Nucl Med 17 (1992) 41-44
9. 186Re-etidronate. Efficacy of palliative radionuclide therapy for painful bone metastases. Q J Nucl Med 45 (2001) 84-90
10. McEwan A.J. Use of radionuclides for the palliation of bone metastases. Semin Radiat Oncol 10 (2000) 103-114
11. 186Re complex of 1-hydroxyethylidene-1,1-diphosphonate for treatment of painful osseous metastases. Radioisotopes 44 (1995) 514-522
12. De Winter F., Brans B., Van De Wiele C., and Dierckx R.A. Visualization of the stomach on rhenium-186 HEDP imaging after therapy for metastasized prostate carcinoma. Clin Nucl Med 24 (1999) 898-899
13. Limouris G.S., and Skukla S.K. Gastric uptake during Re-186 HEDP bone scintigraphy. Anticancer Res 17 (1997) 1779-1781
14. Ogawa K., Mukai T., Arano Y., Hanaoka H., Hashimoto K., Nishimura H., et al. Design of radiopharmaceutical for the palliation of painful bone metastases: rhenium-186-labeled bisphosphonate derivative. J Labelled Compd Radiopharm 47 (2004) 753-761
15. 3-conjugated bisphosphonate for the palliation of metastatic bone pain based on the concept of bifunctional radiopharmaceuticals. Bioconjug Chem 16 (2005) 751-757
16. Ogawa K., Mukai T., Arano Y., Otaka A., Ueda M., Uehara T., et al. Rhenium-186-monoaminemonoamidedithiol-conjugated bisphosphonate derivatives for bone pain palliation. Nucl Med Biol 33 (2006) 513-520
17. Fogelman I. Diphosphonate bone scanning agents - current concepts. Eur J Nucl Med 7 (1982) 506-509
18. Demirkan B., Baskan Z., Alacacioglu A., Gorken I.B., Bekis R., Ada E., et al. False negative bone scintigraphy in a patient with primary breast cancer: a possible transient phenomenon of bisphosphonate (alendronate) treatment. Tumori 91 (2005) 77-80
19. Koizumi M., and Ogata E. Bisphosphonate effect on bone scintigraphy. J Nucl Med 37 (1996) 401
20. Koyano H., Schimizu T., and Shishiba Y. The bisphosphonate dilemma. J Nucl Med 36 (1995) 705-706
21. 99mTc-hydroxymethylene bisphosphonate bone scintigraphy. A prospective study. Rev Rhum Engl Ed 62 (1995) 99-104
22. Pecherstorfer M., Schilling T., Janisch S., Woloszczuk W., Baumgartner G., Ziegler R., et al. Effect of clodronate treatment on bone scintigraphy in metastatic breast cancer. J Nucl Med 34 (1993) 1039-1044
23. Adami S. Bisphosphonates in prostate carcinoma. Cancer 80 (1997) 1674-1679
24. Uehara T., Koike M., Nakata H., Miyamoto S., Motoishi S., Hashimoto K., et al. In vivo recognition of cyclopentadienyltricarbonylrhenium (CpTR) derivatives. Nucl Med Biol 30 (2003) 327-334
25. 99mTc with an in situ CO source: application to a serotonergic receptor ligand. Angew Chem Int Ed Engl 40 (2001) 3062-3066
26. Kieczykowski G.R., Jobson R.B., Melillo D.G., Reinhold D.F., Grenda V.J., and Shinkai I. Preparation of (4-amino-1-hydroxybutylidene)bisphosphonic acid sodium salt, MK-217 (alendronate sodium). An improved procedure for the preparation of 1-hydroxy-1,1-bisphosphonic acids. J Org Chem 60 (1995) 8310-8312
27. Chong W.K., and Cunningham D.A. Case report: intravenous etidronate as a cause of poor uptake on bone scanning, with a review of the literature. Clin Radiol 44 (1991) 268-270
28. Deutsch E., Libson K., Vanderheyden J.L., Ketring A.R., and Maxon H.R. The chemistry of rhenium and technetium as related to the use of isotopes of these elements in therapeutic and diagnostic nuclear medicine. Int J Rad Appl Instrum B 13 (1986) 465-477
29. Cagle D.W., Kennel S.J., Mirzadeh S., Alford J.M., and Wilson L.J. In vivo studies of fullerene-based materials using endohedral metallofullerene radiotracers. Proc Natl Acad Sci U S A 96 (1999) 5182-5187
30. x and its biodistribution studies. Nucl Med Biol 29 (2002) 707-710
31. Horiuchi K., Saji H., and Yokoyama A. Tc(V)-DMS tumor localization mechanism: a pH-sensitive Tc(V)-DMS-enhanced target/nontarget ratio by glucose-mediated acidosis. Nucl Med Biol 25 (1998) 549-555
32. Horiuchi K., Yomoda I., Ohta H., Endo K., and Yokoyama A. Search for polynuclear pentavalent technetium complex of dimercaptosuccinic acid [Tc(V)-DMS] tumour localization mechanism: I. Medullary thyroid carcinoma animal model. Eur J Nucl Med 18 (1991) 796-800
33. Troehler U., Bonjour J.P., and Fleisch H. Renal secretion of diphosphonates in rats. Kidney Int 8 (1975) 6-13
34. Kino I., Kato Y., Lin J.H., and Sugiyama Y. Renal handling of biphosphonate alendronate in rats. Biopharm Drug Dispos 20 (1999) 193-198
35. Lin J.H., Chen I.W., Deluna F.A., and Hichens M. Renal handling of alendronate in rats. An uncharacterized renal transport system. Drug Metab Dispos 20 (1992) 608-613